ProCE Banner Activity

Available and Emerging Treatment Options in IDH-Mutant and FLT3-Mutant AML

Slideset Download
In this downloadable slideset, Eytan M. Stein, MD, provides expert insights and guidance on individualizing treatment for patients with AML with FLT3 or IDH1/2 mutations.

Released: May 31, 2019

Expiration: May 29, 2020

Share

Faculty

Eytan M. Stein

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Agios Pharmaceuticals

Boston Biomedical

Celgene TEXT Only

Daiichi Sankyo, Inc.

Faculty Disclosure

Primary Author

Eytan M. Stein, MD

Chief, Leukemia Service
Director, Program for Drug Development in Leukemia
Memorial Sloan Kettering Cancer Center
New York, New York